Eli Lilly’s Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official — and Novo Nordisk Has a Problem
Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication…
Novo Nordisk CEO Dustar: Obesity Has Eclipsed Diabetes at ADA as Lilly’s Retatrutide Hits 28.3% Weight Loss — BigGo Finance
When the chief executive of the world’s most valuable obesity-drug company admits he’s surprised that a diabetes conference…
Oral Weight-Loss Drug Battle: Novo Nordisk vs Eli Lilly’s New Treatments – News and Statistics
Apr 5, 2026 The competition between Novo Nordisk and Eli Lilly for dominance in the weight-loss medication sector…
Novo Nordisk’s triple agonist delivers up to 19.7% weight loss
Novo Nordisk’s triple agonist UBT251 delivered a mean weight loss of 19.7% after 24 weeks in a Phase…